Home > Cardiology > AHA: Biomarker highly predictive of dapagliflozin response in HFrEF

AHA: Biomarker highly predictive of dapagliflozin response in HFrEF

Expert
David Berg, Brigham and Women's Hospital, Harvard Medical School, Boston
Conference
AHA 2021
Trial
DAPA-HF


© 2023 The Author(s). Published by Medicom Medical Publishers.
User license: Creative Commons Attribution – NonCommercial (CC BY-NC 4.0)


Posted on